The U.S. Food and Drug Administration announced Wednesday it had amended the emergency-use authorization (EUA) for Pfizer's COVID-19 vaccine.
The amended EUA will allow administration of single booster doses at least six months from completion of the primary series.
Eligible individuals under the amended EUA include people of 65 years of age or older, those younger than 65 who are at high risk of experiencing severe COVID-19 symptoms and anyone of any age whose work involves frequent exposure to the virus, placing them at high risk of serious complications relating to COVID-19.
"Today's action demonstrates that science and the currently available data continue to guide the FDA's decision-making for COVID-19 vaccines during the pandemic," said Acting FDA Commissioner Dr. Janet Woodcock in a statement on Wednesday. "This pandemic is dynamic and evolving, with new data about vaccine safety and effectiveness becoming available every day."
For more information on the FDA's amended EUA, click here.
